PMID- 28953649
OWN - NLM
STAT- MEDLINE
DCOM- 20171016
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 39
DP  - 2017 Sep
TI  - Efficacy of escitalopram monotherapy in the treatment of major depressive 
      disorder: A pooled analysis of 4 Chinese clinical trials.
PG  - e8142
LID - 10.1097/MD.0000000000008142 [doi]
LID - e8142
AB  - This study aimed to evaluate the efficacy of escitalopram monotherapy in the 
      treatment of major depressive disorder (MDD) on the basis of pooled data analysis 
      of 4 Chinese clinical trials.A total of 649 outpatients with MDD score of >/=18 at 
      the 17-item Hamilton Depression Rating Scale (HAMD17) were included across 4 
      eligible studies. Patients were treated with 10 mg/day escitalopram for 2 weeks, 
      and then 20 mg/day escitalopram was administered if the clinical response was 
      poor.The change in total HAMD17 score was significantly greater in moderate MDD 
      group than in other subgroups (P < .001), but the proportion of responders and 
      remission rate in moderate MDD group were markedly lower than in mild MDD group. 
      As compared to patients with concomitant anxiety, anxiety free patients showed 
      significant improvement in total HAMD17 score at days 14 and 28 (P < .05). 
      However, there was no significant difference in the change of total HAMD17 score 
      at day 7 and the end of study. According to clinical global impression (CGI) 
      score, the total response rate (very much improved and much improved) was 86.7%. 
      There were 479 adverse events (AEs), but serious AEs were not observed. A total 
      of 3.39% (22/649) of patients withdrew from these studies due to AEs. The most 
      common (incidence >/=2.0%) AEs were nausea, dry mouth, somnolence, dizziness, 
      fatigue, dyspepsia, liver dysfunction, and loss of appetite.Escitalopram 
      monotherapy is effective and safe in the treatment of MDD in Chinese patients, 
      and therapeutic efficacy is dependent on the severity of MDD. Further study is 
      needed to identify better predictors of therapeutic responses.
FAU - Li, Guanjun
AU  - Li G
AD  - Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine 
      Department of Health Statistics and Social Medicine, School of Public Health, 
      Fudan University, Shanghai, China.
FAU - Shen, Yifeng
AU  - Shen Y
FAU - Luo, Jianfeng
AU  - Luo J
FAU - Li, Huafang
AU  - Li H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - China
MH  - *Citalopram/administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - *Depressive Disorder, Major/diagnosis/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Monitoring/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Remission Induction/methods
MH  - Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC5626292
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/09/28 06:00
MHDA- 2017/10/17 06:00
PMCR- 2017/09/29
CRDT- 2017/09/28 06:00
PHST- 2017/09/28 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
PHST- 2017/09/29 00:00 [pmc-release]
AID - 00005792-201709290-00042 [pii]
AID - MD-D-17-02825 [pii]
AID - 10.1097/MD.0000000000008142 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Sep;96(39):e8142. doi: 10.1097/MD.0000000000008142.